시장보고서
상품코드
1791614

세계의 생명과학 기업용 데이터 수익화 솔루션 시장

Data Monetization Solutions for Life Science Companies

발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 158 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 생명과학 기업용 데이터 수익화 솔루션 시장은 2030년까지 11억 달러에 이를 전망

2024년에 4억 1,690만 달러로 추정되는 생명과학 기업용 데이터 수익화 솔루션 세계 시장은 분석 기간인 2024-2030년 CAGR 17.5%로 성장하여 2030년에는 11억 달러에 이를 것으로 예측됩니다. 본 보고서에서 분석한 부문 중 하나인 간접 데이터 수익화는 CAGR 20.1%를 나타내고, 분석 기간 종료시에는 7억 4,480만 달러에 이를 것으로 예측됩니다. 직접 데이터 수익화 부문의 성장률은 분석 기간중 CAGR13.1%로 추정됩니다.

미국 시장은 1억 960만 달러로 추정, 중국은 CAGR 16.4%로 성장 예측

미국의 생명과학 기업용 데이터 수익화 솔루션 시장은 2024년에 1억 960만 달러로 평가되었습니다. 세계 2위 경제대국인 중국은 2030년까지 1억 6,770만 달러 규모에 이를 것으로 예측되며, 분석 기간인 2024-2030년 CAGR은 16.4%로 추정됩니다. 기타 주목해야 할 지역별 시장으로는 일본과 캐나다가 있으며, 분석 기간중 CAGR은 각각 16.5%와 14.8%를 보일 것으로 예측됩니다. 유럽에서는 독일이 CAGR 약 12.5%를 보일 전망입니다.

세계의 생명과학 기업용 데이터 수익화 솔루션-주요 동향과 성장 촉진요인 정리

데이터 수익화가 생명과학 산업을 변화시키는 이유

제약사, 생명공학 기업, 임상연구기관 등 생명과학 기업들은 임상시험, 유전체학, 신약개발, 환자 모니터링을 통해 방대한 양의 데이터를 생성하고 있습니다. 데이터 수익화를 통해 이들 기업은 새로운 수익원을 확보하고, 연구개발(R&:D)을 최적화하며, AI 기반 인사이트를 통해 환자 결과를 개선할 수 있습니다. 생명과학 기업들은 익명화되고 구조화된 데이터 세트를 활용하여 의약품 개발을 가속화하고, 정밀의료를 강화하며, 개인화된 헬스케어 솔루션의 혁신을 촉진할 수 있습니다.

디지털 헬스, RWE(Real World Evidence) 활용, AI를 활용한 진단으로의 전환은 데이터 수익화 전략의 필요성을 더욱 높이고 있습니다. 생명과학 기업들은 의료 제공업체, 지불자, 규제 당국과의 전략적 협업을 통해 데이터 기반 지식을 활용하여 의사결정 개선, 시장 동향 파악, 임상 연구 효율화를 도모하고 있습니다. 또한, 클라우드 기반 분석 플랫폼과 블록체인 기반 데이터 마켓플레이스의 채택이 증가함에 따라 안전하고 컴플라이언스를 준수하는 데이터 거래가 촉진되고, 생명과학 데이터의 윤리적 수익화가 실현되고 있습니다.

생명과학 데이터 수익화 분야의 최신 혁신은 무엇인가?

AI, 머신러닝(ML), 데이터 상호운용성의 발전은 생명과학 분야의 데이터 수익화 능력을 크게 향상시켰습니다. 가장 주목할 만한 혁신 중 하나는 AI 모델이 민감한 환자 정보를 공개하지 않고도 여러 기관에 분산된 데이터 세트를 분석할 수 있도록 하는 협업 학습입니다. 이러한 접근 방식은 데이터 프라이버시 규제를 준수하면서 신약 개발, 바이오마커 식별, 개인 맞춤형 치료 계획 수립을 위한 협업을 향상시킵니다.

또 다른 돌파구는 익명화된 데이터 세트를 연구 목적으로 안전하게 거래할 수 있는 토큰화된 의료 데이터 거래소의 개발입니다. 블록체인 기술은 투명성, 데이터 무결성, 접근 제어를 보장하고, 생명과학 기업들이 허가된 이해관계자들과 유전체, 단백질체학, 임상시험 데이터를 공유할 수 있게 해줍니다. 또한, AI 기반 데이터 정합성 도구는 이기종 데이터 세트의 통합을 최적화하여 기업이 이기종 소스에서 실용적인 인사이트를 도출할 수 있도록 돕습니다. 합성 데이터(프라이버시를 침해하지 않고 실제 환자 정보를 모방한 AI가 생성한 데이터 세트)의 사용도 데이터 수익화를 위한 윤리적이고 규제에 부합하는 대안으로 각광받고 있습니다.

시장 동향과 규제 정책은 생명과학 데이터 수익화에 어떤 영향을 미치고 있는가?

근거 기반 의료, 리얼월드데이터(RWD) 활용, AI 기반 연구에 대한 관심이 높아지면서 생명과학 분야의 데이터 수익화 전략 도입이 가속화되고 있습니다. 생명과학 기업들은 의료기관, 학술 기관, AI 기업들과 협력하여 대규모 데이터 분석을 통해 약효 및 환자 계층화 개선에 힘쓰고 있습니다.

HIPAA, GDPR(EU 개인정보보호규정), FDA의 Real-World Evidence Program과 같은 규제 프레임워크는 데이터 수익화 정책을 크게 형성하고 있습니다. 기업은 의료 데이터 자산을 상업화하면서 컴플라이언스를 준수하기 위해 데이터 익명화, 환자 동의, 윤리적 사용에 대한 엄격한 가이드라인을 준수해야 합니다. 또한, 데이터 거버넌스 이니셔티브와 FHIR(Fast Healthcare Interoperability Resources)과 같은 상호운용성 표준의 등장으로 다양한 이해관계자간의 원활한 데이터 공유와 수익화가 촉진되고 있습니다.

생명과학 기업용 데이터 수익화 솔루션 시장의 성장을 주도하는 요인은 무엇인가?

생명과학 기업의 데이터 수익화 시장의 성장은 AI 기반 분석의 활용 확대, 유전체 및 신약 개발의 발전, 실제 데이터 인사이트에 대한 수요 증가에 기인하고 있습니다. 개인 맞춤형 의료와 정밀의료의 부상으로 표적 치료와 치료 최적화에 도움이 되는 구조화된 고품질 데이터 세트의 필요성이 더욱 커지고 있습니다.

임상 연구, 약물감시, 집단 건강 관리에서 데이터 수익화가 활용되는 등 최종 용도의 확대도 중요한 요소입니다. AI를 활용한 데이터 마켓플레이스, 클라우드 기반 분석, 블록체인으로 보호되는 데이터 트랜잭션의 통합으로 도입이 가속화되고 있습니다. 또한, 제약사, 바이오테크 스타트업, 데이터 보안 기업 간의 전략적 제휴는 혁신을 촉진하고, 생명과학 데이터 수익화 솔루션이 컴플라이언스와 윤리적 무결성을 유지하면서 업계의 요구에 부합하도록 돕고 있습니다.

부문

유형(간접 데이터 수익화, 직접 데이터 수익화), 전개(클라우드 전개, On-Premise 전개), 시설 규모(대규모 시설, 중소규모 시설)

조사 대상 기업 예

  • Accenture plc
  • Cerner Corporation
  • Cisco Systems, Inc.
  • GE Healthcare
  • Google LLC
  • Infosys Limited
  • McKesson Corporation
  • Medidata Solutions
  • Microsoft Corporation
  • OpenText Corporation
  • Oracle Corporation
  • Particle Health, Inc.
  • Salesforce, Inc.
  • SAP SE
  • SAS Institute Inc.
  • Scientist.com
  • Siemens AG
  • Snowflake Inc.
  • TIBCO Software Inc.
  • Veeva Systems Inc.

AI 통합

Global Industry Analysts는 유효한 전문가 컨텐츠와 AI툴에 의해서, 시장 정보와 경쟁 정보를 변혁하고 있습니다.

Global Industry Analysts는 LLM나 업계 고유 SLM를 조회하는 일반적인 규범에 따르는 대신에, 비디오 기록, 블로그, 검색 엔진 조사, 방대한 양의 기업, 제품/서비스, 시장 데이터 등, 전 세계 전문가로부터 수집한 컨텐츠 리포지토리를 구축했습니다.

관세 영향 계수

Global Industry Analysts는 본사 소재지, 제조거점, 수출입(완제품 및 OEM)을 기준으로 기업의 경쟁력 변화를 예측했습니다. 이러한 복잡하고 다면적인 시장 역학은 수익원가(COGS) 증가, 수익성 하락, 공급망 재편 등 미시적, 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예측됩니다.

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 기타 유럽
  • 아시아태평양
  • 기타 지역

제4장 경쟁

LSH 25.08.21

Global Data Monetization Solutions for Life Science Companies Market to Reach US$1.1 Billion by 2030

The global market for Data Monetization Solutions for Life Science Companies estimated at US$416.9 Million in the year 2024, is expected to reach US$1.1 Billion by 2030, growing at a CAGR of 17.5% over the analysis period 2024-2030. Indirect Data Monetization, one of the segments analyzed in the report, is expected to record a 20.1% CAGR and reach US$744.8 Million by the end of the analysis period. Growth in the Direct Data Monetization segment is estimated at 13.1% CAGR over the analysis period.

The U.S. Market is Estimated at US$109.6 Million While China is Forecast to Grow at 16.4% CAGR

The Data Monetization Solutions for Life Science Companies market in the U.S. is estimated at US$109.6 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$167.7 Million by the year 2030 trailing a CAGR of 16.4% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 16.5% and 14.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 12.5% CAGR.

Global Data Monetization Solutions for Life Science Companies - Key Trends & Growth Drivers Summarized

Why Is Data Monetization Transforming the Life Sciences Industry?

Life science companies, including pharmaceutical firms, biotechnology enterprises, and clinical research organizations, generate vast amounts of data through clinical trials, genomics, drug discovery, and patient monitoring. Data monetization is enabling these organizations to unlock new revenue streams, optimize research and development (R&D), and improve patient outcomes through AI-driven insights. By leveraging anonymized and structured datasets, life science firms can accelerate drug development, enhance precision medicine, and drive innovation in personalized healthcare solutions.

The shift toward digital health, real-world evidence (RWE) utilization, and AI-powered diagnostics has further intensified the need for data monetization strategies. Through strategic collaborations with healthcare providers, payers, and regulatory agencies, life science companies are leveraging data-driven insights to improve decision-making, identify market trends, and streamline clinical research. The growing adoption of cloud-based analytics platforms and blockchain-enabled data marketplaces is also facilitating secure and compliant data transactions, ensuring ethical monetization of life science data.

What Are the Latest Innovations in Life Sciences Data Monetization?

Advancements in AI, machine learning (ML), and data interoperability have significantly enhanced the capabilities of data monetization in life sciences. One of the most notable innovations is federated learning, which allows AI models to analyze decentralized datasets across multiple institutions without exposing sensitive patient information. This approach is improving collaboration in drug discovery, biomarker identification, and personalized treatment planning while maintaining compliance with data privacy regulations.

Another breakthrough is the development of tokenized health data exchanges, where anonymized datasets can be securely traded for research purposes. Blockchain technology is ensuring transparency, data integrity, and controlled access, enabling life science companies to share genomic, proteomic, and clinical trial data with authorized stakeholders. Additionally, AI-powered data harmonization tools are optimizing the integration of heterogeneous datasets, allowing companies to derive actionable insights from disparate sources. The use of synthetic data-AI-generated datasets that mimic real patient information without compromising privacy-is also gaining traction as an ethical and regulatory-compliant alternative for data monetization.

How Are Market Trends and Regulatory Policies Influencing Life Science Data Monetization?

The increasing emphasis on evidence-based medicine, real-world data (RWD) utilization, and AI-driven research has propelled the adoption of data monetization strategies in the life sciences sector. Life science companies are partnering with healthcare organizations, academic institutions, and AI firms to leverage large-scale data analytics for improved drug efficacy and patient stratification.

Regulatory frameworks such as HIPAA, GDPR, and the FDA’s Real-World Evidence Program have significantly shaped data monetization policies. Companies must adhere to strict guidelines on data anonymization, patient consent, and ethical usage to ensure compliance while commercializing health data assets. Additionally, the rise of data governance initiatives and interoperability standards such as FHIR (Fast Healthcare Interoperability Resources) has facilitated seamless data sharing and monetization across different stakeholders.

What Is Driving the Growth of the Data Monetization Solutions for Life Science Companies Market?

The growth in the data monetization market for life science companies is driven by the increasing use of AI-driven analytics, advancements in genomics and drug discovery, and the growing demand for real-world data insights. The rise of personalized medicine and precision healthcare has further fueled the need for structured, high-quality datasets that can inform targeted therapies and treatment optimization.

End-use expansion is another key factor, with data monetization being leveraged in clinical research, pharmacovigilance, and population health management. The integration of AI-powered data marketplaces, cloud-based analytics, and blockchain-secured data transactions is accelerating adoption. Additionally, strategic partnerships between pharmaceutical firms, biotech startups, and data security companies are fostering innovation, ensuring that life science data monetization solutions align with industry needs while maintaining compliance and ethical integrity.

SCOPE OF STUDY:

The report analyzes the Data Monetization Solutions for Life Science Companies market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Type (Indirect Data Monetization, Direct Data Monetization); Deployment (Cloud Deployment, On-Premises Deployment); Facility Size (Large Facilities, Small and Medium Facilities)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 32 Featured) -

  • Accenture plc
  • Cerner Corporation
  • Cisco Systems, Inc.
  • GE Healthcare
  • Google LLC
  • Infosys Limited
  • McKesson Corporation
  • Medidata Solutions
  • Microsoft Corporation
  • OpenText Corporation
  • Oracle Corporation
  • Particle Health, Inc.
  • Salesforce, Inc.
  • SAP SE
  • SAS Institute Inc.
  • Scientist.com
  • Siemens AG
  • Snowflake Inc.
  • TIBCO Software Inc.
  • Veeva Systems Inc.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Data Monetization Solutions for Life Science Companies - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Explosion of Omics, Clinical, and Real-World Data Throws the Spotlight on Data Monetization as a Strategic Growth Lever in Life Sciences
    • Rising R&D Costs and Lengthening Drug Development Timelines Strengthen the Business Case for Commercializing Proprietary Data Assets
    • Increased Adoption of Real-World Evidence (RWE) and Real-World Data (RWD) for Regulatory Submissions Expands Monetization Opportunities
    • Growing Demand for Patient-Centric and Precision Medicine Models Drives the Need for High-Granularity, Monetizable Datasets
    • Integration of Clinical Trial, Genomic, and Longitudinal Health Data Enables Development of High-Value, Multi-Dimensional Data Products
    • Digital Transformation Across Pharma and Biotech Spurs Investment in Data Lakes, Marketplaces, and Data-as-a-Service (DaaS) Platforms
    • Emergence of AI-Driven Drug Discovery Models Creates Demand for Proprietary, High-Quality Labeled Datasets
    • Post-Approval Market Surveillance and Pharmacovigilance Programs Leverage Monetized Data Streams from Internal and Partner Systems
    • Expansion of Companion Diagnostics and Biomarker Discovery Initiatives Fuels Commercialization of Clinical and Lab Data Assets
    • Integration of EHR, Claims, Imaging, and Wearable Data Sources Increases Scope for Licensing and Data Sharing Agreements
    • Shift Toward Outcome-Based and Risk-Sharing Agreements Drives Life Sciences Companies to Monetize Insights-Driven Data Products
    • Adoption of Federated Learning and Privacy-Preserving Analytics Enables Data Sharing Without Compromising IP or Patient Privacy
    • Rising Regulatory Pressure for Transparent and Explainable AI Strengthens Demand for Traceable, Governed Data Sources
    • Growth of Digital Therapeutics and Connected Health Devices Adds New Monetizable Data Streams from Patient Usage Patterns
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Data Monetization Solutions for Life Science Companies Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Data Monetization Solutions for Life Science Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World 6-Year Perspective for Data Monetization Solutions for Life Science Companies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2025 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Indirect Data Monetization by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 5: World 6-Year Perspective for Indirect Data Monetization by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 6: World Recent Past, Current & Future Analysis for Direct Data Monetization by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 7: World 6-Year Perspective for Direct Data Monetization by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Cloud Deployment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World 6-Year Perspective for Cloud Deployment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for On-Premises Deployment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 11: World 6-Year Perspective for On-Premises Deployment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 12: World Recent Past, Current & Future Analysis for Large Facilities by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 13: World 6-Year Perspective for Large Facilities by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Small & Medium Facilities by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World 6-Year Perspective for Small & Medium Facilities by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Data Monetization Solutions for Life Science Companies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 16: USA Recent Past, Current & Future Analysis for Data Monetization Solutions for Life Science Companies by Type - Indirect Data Monetization and Direct Data Monetization - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 17: USA 6-Year Perspective for Data Monetization Solutions for Life Science Companies by Type - Percentage Breakdown of Value Sales for Indirect Data Monetization and Direct Data Monetization for the Years 2025 & 2030
    • TABLE 18: USA Recent Past, Current & Future Analysis for Data Monetization Solutions for Life Science Companies by Deployment - Cloud Deployment and On-Premises Deployment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 19: USA 6-Year Perspective for Data Monetization Solutions for Life Science Companies by Deployment - Percentage Breakdown of Value Sales for Cloud Deployment and On-Premises Deployment for the Years 2025 & 2030
    • TABLE 20: USA Recent Past, Current & Future Analysis for Data Monetization Solutions for Life Science Companies by Facility Size - Large Facilities and Small & Medium Facilities - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 21: USA 6-Year Perspective for Data Monetization Solutions for Life Science Companies by Facility Size - Percentage Breakdown of Value Sales for Large Facilities and Small & Medium Facilities for the Years 2025 & 2030
  • CANADA
    • TABLE 22: Canada Recent Past, Current & Future Analysis for Data Monetization Solutions for Life Science Companies by Type - Indirect Data Monetization and Direct Data Monetization - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 23: Canada 6-Year Perspective for Data Monetization Solutions for Life Science Companies by Type - Percentage Breakdown of Value Sales for Indirect Data Monetization and Direct Data Monetization for the Years 2025 & 2030
    • TABLE 24: Canada Recent Past, Current & Future Analysis for Data Monetization Solutions for Life Science Companies by Deployment - Cloud Deployment and On-Premises Deployment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 25: Canada 6-Year Perspective for Data Monetization Solutions for Life Science Companies by Deployment - Percentage Breakdown of Value Sales for Cloud Deployment and On-Premises Deployment for the Years 2025 & 2030
    • TABLE 26: Canada Recent Past, Current & Future Analysis for Data Monetization Solutions for Life Science Companies by Facility Size - Large Facilities and Small & Medium Facilities - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 27: Canada 6-Year Perspective for Data Monetization Solutions for Life Science Companies by Facility Size - Percentage Breakdown of Value Sales for Large Facilities and Small & Medium Facilities for the Years 2025 & 2030
  • JAPAN
    • Data Monetization Solutions for Life Science Companies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 28: Japan Recent Past, Current & Future Analysis for Data Monetization Solutions for Life Science Companies by Type - Indirect Data Monetization and Direct Data Monetization - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 29: Japan 6-Year Perspective for Data Monetization Solutions for Life Science Companies by Type - Percentage Breakdown of Value Sales for Indirect Data Monetization and Direct Data Monetization for the Years 2025 & 2030
    • TABLE 30: Japan Recent Past, Current & Future Analysis for Data Monetization Solutions for Life Science Companies by Deployment - Cloud Deployment and On-Premises Deployment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 31: Japan 6-Year Perspective for Data Monetization Solutions for Life Science Companies by Deployment - Percentage Breakdown of Value Sales for Cloud Deployment and On-Premises Deployment for the Years 2025 & 2030
    • TABLE 32: Japan Recent Past, Current & Future Analysis for Data Monetization Solutions for Life Science Companies by Facility Size - Large Facilities and Small & Medium Facilities - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Japan 6-Year Perspective for Data Monetization Solutions for Life Science Companies by Facility Size - Percentage Breakdown of Value Sales for Large Facilities and Small & Medium Facilities for the Years 2025 & 2030
  • CHINA
    • Data Monetization Solutions for Life Science Companies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 34: China Recent Past, Current & Future Analysis for Data Monetization Solutions for Life Science Companies by Type - Indirect Data Monetization and Direct Data Monetization - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 35: China 6-Year Perspective for Data Monetization Solutions for Life Science Companies by Type - Percentage Breakdown of Value Sales for Indirect Data Monetization and Direct Data Monetization for the Years 2025 & 2030
    • TABLE 36: China Recent Past, Current & Future Analysis for Data Monetization Solutions for Life Science Companies by Deployment - Cloud Deployment and On-Premises Deployment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 37: China 6-Year Perspective for Data Monetization Solutions for Life Science Companies by Deployment - Percentage Breakdown of Value Sales for Cloud Deployment and On-Premises Deployment for the Years 2025 & 2030
    • TABLE 38: China Recent Past, Current & Future Analysis for Data Monetization Solutions for Life Science Companies by Facility Size - Large Facilities and Small & Medium Facilities - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: China 6-Year Perspective for Data Monetization Solutions for Life Science Companies by Facility Size - Percentage Breakdown of Value Sales for Large Facilities and Small & Medium Facilities for the Years 2025 & 2030
  • EUROPE
    • Data Monetization Solutions for Life Science Companies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 40: Europe Recent Past, Current & Future Analysis for Data Monetization Solutions for Life Science Companies by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 41: Europe 6-Year Perspective for Data Monetization Solutions for Life Science Companies by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2025 & 2030
    • TABLE 42: Europe Recent Past, Current & Future Analysis for Data Monetization Solutions for Life Science Companies by Type - Indirect Data Monetization and Direct Data Monetization - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 43: Europe 6-Year Perspective for Data Monetization Solutions for Life Science Companies by Type - Percentage Breakdown of Value Sales for Indirect Data Monetization and Direct Data Monetization for the Years 2025 & 2030
    • TABLE 44: Europe Recent Past, Current & Future Analysis for Data Monetization Solutions for Life Science Companies by Deployment - Cloud Deployment and On-Premises Deployment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Europe 6-Year Perspective for Data Monetization Solutions for Life Science Companies by Deployment - Percentage Breakdown of Value Sales for Cloud Deployment and On-Premises Deployment for the Years 2025 & 2030
    • TABLE 46: Europe Recent Past, Current & Future Analysis for Data Monetization Solutions for Life Science Companies by Facility Size - Large Facilities and Small & Medium Facilities - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 47: Europe 6-Year Perspective for Data Monetization Solutions for Life Science Companies by Facility Size - Percentage Breakdown of Value Sales for Large Facilities and Small & Medium Facilities for the Years 2025 & 2030
  • FRANCE
    • Data Monetization Solutions for Life Science Companies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 48: France Recent Past, Current & Future Analysis for Data Monetization Solutions for Life Science Companies by Type - Indirect Data Monetization and Direct Data Monetization - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 49: France 6-Year Perspective for Data Monetization Solutions for Life Science Companies by Type - Percentage Breakdown of Value Sales for Indirect Data Monetization and Direct Data Monetization for the Years 2025 & 2030
    • TABLE 50: France Recent Past, Current & Future Analysis for Data Monetization Solutions for Life Science Companies by Deployment - Cloud Deployment and On-Premises Deployment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: France 6-Year Perspective for Data Monetization Solutions for Life Science Companies by Deployment - Percentage Breakdown of Value Sales for Cloud Deployment and On-Premises Deployment for the Years 2025 & 2030
    • TABLE 52: France Recent Past, Current & Future Analysis for Data Monetization Solutions for Life Science Companies by Facility Size - Large Facilities and Small & Medium Facilities - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 53: France 6-Year Perspective for Data Monetization Solutions for Life Science Companies by Facility Size - Percentage Breakdown of Value Sales for Large Facilities and Small & Medium Facilities for the Years 2025 & 2030
  • GERMANY
    • Data Monetization Solutions for Life Science Companies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 54: Germany Recent Past, Current & Future Analysis for Data Monetization Solutions for Life Science Companies by Type - Indirect Data Monetization and Direct Data Monetization - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 55: Germany 6-Year Perspective for Data Monetization Solutions for Life Science Companies by Type - Percentage Breakdown of Value Sales for Indirect Data Monetization and Direct Data Monetization for the Years 2025 & 2030
    • TABLE 56: Germany Recent Past, Current & Future Analysis for Data Monetization Solutions for Life Science Companies by Deployment - Cloud Deployment and On-Premises Deployment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Germany 6-Year Perspective for Data Monetization Solutions for Life Science Companies by Deployment - Percentage Breakdown of Value Sales for Cloud Deployment and On-Premises Deployment for the Years 2025 & 2030
    • TABLE 58: Germany Recent Past, Current & Future Analysis for Data Monetization Solutions for Life Science Companies by Facility Size - Large Facilities and Small & Medium Facilities - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 59: Germany 6-Year Perspective for Data Monetization Solutions for Life Science Companies by Facility Size - Percentage Breakdown of Value Sales for Large Facilities and Small & Medium Facilities for the Years 2025 & 2030
  • ITALY
    • TABLE 60: Italy Recent Past, Current & Future Analysis for Data Monetization Solutions for Life Science Companies by Type - Indirect Data Monetization and Direct Data Monetization - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 61: Italy 6-Year Perspective for Data Monetization Solutions for Life Science Companies by Type - Percentage Breakdown of Value Sales for Indirect Data Monetization and Direct Data Monetization for the Years 2025 & 2030
    • TABLE 62: Italy Recent Past, Current & Future Analysis for Data Monetization Solutions for Life Science Companies by Deployment - Cloud Deployment and On-Premises Deployment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Italy 6-Year Perspective for Data Monetization Solutions for Life Science Companies by Deployment - Percentage Breakdown of Value Sales for Cloud Deployment and On-Premises Deployment for the Years 2025 & 2030
    • TABLE 64: Italy Recent Past, Current & Future Analysis for Data Monetization Solutions for Life Science Companies by Facility Size - Large Facilities and Small & Medium Facilities - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 65: Italy 6-Year Perspective for Data Monetization Solutions for Life Science Companies by Facility Size - Percentage Breakdown of Value Sales for Large Facilities and Small & Medium Facilities for the Years 2025 & 2030
  • UNITED KINGDOM
    • Data Monetization Solutions for Life Science Companies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 66: UK Recent Past, Current & Future Analysis for Data Monetization Solutions for Life Science Companies by Type - Indirect Data Monetization and Direct Data Monetization - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 67: UK 6-Year Perspective for Data Monetization Solutions for Life Science Companies by Type - Percentage Breakdown of Value Sales for Indirect Data Monetization and Direct Data Monetization for the Years 2025 & 2030
    • TABLE 68: UK Recent Past, Current & Future Analysis for Data Monetization Solutions for Life Science Companies by Deployment - Cloud Deployment and On-Premises Deployment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: UK 6-Year Perspective for Data Monetization Solutions for Life Science Companies by Deployment - Percentage Breakdown of Value Sales for Cloud Deployment and On-Premises Deployment for the Years 2025 & 2030
    • TABLE 70: UK Recent Past, Current & Future Analysis for Data Monetization Solutions for Life Science Companies by Facility Size - Large Facilities and Small & Medium Facilities - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 71: UK 6-Year Perspective for Data Monetization Solutions for Life Science Companies by Facility Size - Percentage Breakdown of Value Sales for Large Facilities and Small & Medium Facilities for the Years 2025 & 2030
  • REST OF EUROPE
    • TABLE 72: Rest of Europe Recent Past, Current & Future Analysis for Data Monetization Solutions for Life Science Companies by Type - Indirect Data Monetization and Direct Data Monetization - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 73: Rest of Europe 6-Year Perspective for Data Monetization Solutions for Life Science Companies by Type - Percentage Breakdown of Value Sales for Indirect Data Monetization and Direct Data Monetization for the Years 2025 & 2030
    • TABLE 74: Rest of Europe Recent Past, Current & Future Analysis for Data Monetization Solutions for Life Science Companies by Deployment - Cloud Deployment and On-Premises Deployment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Rest of Europe 6-Year Perspective for Data Monetization Solutions for Life Science Companies by Deployment - Percentage Breakdown of Value Sales for Cloud Deployment and On-Premises Deployment for the Years 2025 & 2030
    • TABLE 76: Rest of Europe Recent Past, Current & Future Analysis for Data Monetization Solutions for Life Science Companies by Facility Size - Large Facilities and Small & Medium Facilities - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 77: Rest of Europe 6-Year Perspective for Data Monetization Solutions for Life Science Companies by Facility Size - Percentage Breakdown of Value Sales for Large Facilities and Small & Medium Facilities for the Years 2025 & 2030
  • ASIA-PACIFIC
    • Data Monetization Solutions for Life Science Companies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 78: Asia-Pacific Recent Past, Current & Future Analysis for Data Monetization Solutions for Life Science Companies by Type - Indirect Data Monetization and Direct Data Monetization - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 79: Asia-Pacific 6-Year Perspective for Data Monetization Solutions for Life Science Companies by Type - Percentage Breakdown of Value Sales for Indirect Data Monetization and Direct Data Monetization for the Years 2025 & 2030
    • TABLE 80: Asia-Pacific Recent Past, Current & Future Analysis for Data Monetization Solutions for Life Science Companies by Deployment - Cloud Deployment and On-Premises Deployment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Asia-Pacific 6-Year Perspective for Data Monetization Solutions for Life Science Companies by Deployment - Percentage Breakdown of Value Sales for Cloud Deployment and On-Premises Deployment for the Years 2025 & 2030
    • TABLE 82: Asia-Pacific Recent Past, Current & Future Analysis for Data Monetization Solutions for Life Science Companies by Facility Size - Large Facilities and Small & Medium Facilities - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 83: Asia-Pacific 6-Year Perspective for Data Monetization Solutions for Life Science Companies by Facility Size - Percentage Breakdown of Value Sales for Large Facilities and Small & Medium Facilities for the Years 2025 & 2030
  • REST OF WORLD
    • TABLE 84: Rest of World Recent Past, Current & Future Analysis for Data Monetization Solutions for Life Science Companies by Type - Indirect Data Monetization and Direct Data Monetization - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 85: Rest of World 6-Year Perspective for Data Monetization Solutions for Life Science Companies by Type - Percentage Breakdown of Value Sales for Indirect Data Monetization and Direct Data Monetization for the Years 2025 & 2030
    • TABLE 86: Rest of World Recent Past, Current & Future Analysis for Data Monetization Solutions for Life Science Companies by Deployment - Cloud Deployment and On-Premises Deployment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Rest of World 6-Year Perspective for Data Monetization Solutions for Life Science Companies by Deployment - Percentage Breakdown of Value Sales for Cloud Deployment and On-Premises Deployment for the Years 2025 & 2030
    • TABLE 88: Rest of World Recent Past, Current & Future Analysis for Data Monetization Solutions for Life Science Companies by Facility Size - Large Facilities and Small & Medium Facilities - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 89: Rest of World 6-Year Perspective for Data Monetization Solutions for Life Science Companies by Facility Size - Percentage Breakdown of Value Sales for Large Facilities and Small & Medium Facilities for the Years 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제